Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval. DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction. A transcript of their conversation can be found at Aventine.org/podcast.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related